Collaboration advances EMA601 as potential first-in-class stroke therapy
Educatie
University of Würzburg Mar 30 2026 Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601. University Hospital Würzburg has supported the development of this novel compound from the outset. EMA601 specifically targets the platelet surface receptor glycoprotein VI (GPVI). Studies conducted in Würzburg showed that EMA601 very effectively blocks the
din zilele anterioare